Abstract 3158
Background
Continued smoking after a HNC diagnosis is associated with poorer outcomes. Proximity to tobacco retail outlets is negatively associated with cessation in non-cancer patients (pts) but this has not been evaluated in cancer survivors. We evaluated the impact of tobacco retail access on cessation in HNC pts.
Methods
HNC pts (Princess Margaret Cancer Centre, Toronto, Canada) completed questionnaires at diagnosis and follow up (median 26 months apart) evaluating changes in tobacco use. Validated tobacco retail location data were obtained from Ontario Ministry of Health and pt home addresses were geocoded using ArcGIS 10.6.1, which calculated walking time/distance to nearest vendor and vendor density within 250 meters (m) and 500m from pts. Multivariable logistic regression and Cox proportional hazard models evaluated the impact of vendor availability on cessation and time to quitting after diagnosis respectively, adjusted for significant clinico-demographic and tobacco covariates.
Results
141/450 HNC pts smoked at diagnosis; quit rate after diagnosis was 48%. Mean distance and walking time to a vendor was 1.2 km (range 0-10) and 14 min (range 0-116). On average, there was 1 vendor (range 0-19) within 250m and 3 vendors (range 0-19) within 500m from pts; 33% and 56% of pts lived within 250m and 500m from at least one vendor, respectively. Greater distance (aOR 1.27 per 1000m [95% CI 1.01-1.59] p = 0.04) and increased walking time (aOR 1.02 per min [1.00-1.04] p = 0.04) to a vendor were associated with a higher quit rate at one year. Living near more vendors within 500m was associated with an increasing dose effect on reducing cessation rates at 1 year (aOR 0.90 per vendor [0.82-0.99] p = 0.03). Greater distance (aHR 1.18 per 1000m [1.01-1.38] p = 0.04) and increased walking time (aHR 1.01 per min [1.00-1.03] p = 0.04) to a vendor were also associated with quitting at any time. Living near more vendors within 500m had a trend towards reducing quit rates at any time (aHR 0.94 per vendor [0.88-1.00] p = 0.07).
Conclusions
Close proximity to tobacco retail outlets is associated with reduced cessation rates for HNC survivors. Reducing density of tobacco vendors is a cessation strategy that can positively impact HNC pt outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5152 - Comprehensive Geriatric Assessment (CGA) can categorize elderly glioblastoma (GBM) patients into three groups predicting survival: a monoinstitutional study
Presenter: Eleonora Bergo
Session: Poster Display session 1
Resources:
Abstract
4079 - Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy
Presenter: Gabriela Kramer-marek
Session: Poster Display session 1
Resources:
Abstract
4364 - Upregulation of sFRP3 circulating expression levels correlates survival outcomes in glioblastoma
Presenter: Gema Bruixola
Session: Poster Display session 1
Resources:
Abstract
2327 - Characterization and pre-clinical modeling of genetic aberrations in pediatric gliomas
Presenter: Itai Moshe
Session: Poster Display session 1
Resources:
Abstract
3154 - Preclinical Study of Novel Tetracyclic Small Molecule, CC12, for Brain Cancer
Presenter: Liyun Fann
Session: Poster Display session 1
Resources:
Abstract
5759 - CHLOROBRAIN phase IB trial: The addition of chloroquine, an autophagy inhibitor, to concurrent radiation and temozolomide for newly diagnosed glioblastoma
Presenter: Inge Compter
Session: Poster Display session 1
Resources:
Abstract
1382 - A Phase II Clinical Trial Evaluating the Efficacy and Safety of Apatinib Combined with dose-dense Temozolomide in Recurrent Glioblastoma
Presenter: Yong Wang
Session: Poster Display session 1
Resources:
Abstract
4407 - Phase 0 Trial of Ceritinib in Brain Metastases and Recurrent Glioblastoma
Presenter: Shwetal Mehta
Session: Poster Display session 1
Resources:
Abstract
1469 - Pembrolizumab (Pem) in recurrent high-grade glioma (HGG) patients with mismatch repair deficiency (MMRd): an observational study
Presenter: Mario Caccese
Session: Poster Display session 1
Resources:
Abstract
4217 - Outcome of high-grade gliomas (HGGs) treated into immunotherapeutic early-phase clinical trials (ieCTs): a single-center experience
Presenter: Matteo Simonelli
Session: Poster Display session 1
Resources:
Abstract